Exenatide API Manufacturers

Looking for Exenatide API 141758-74-9?

Description:

Here you will find a list of producers, manufacturers and distributors of Exenatide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Exenatide 

Synonyms:

AC-2993 , Bydureon , Byetta , Exenatide , Exenatide synthetic , Synthetic exendin-4  

Cas Number:

141758-74-9 

DrugBank number:

DB01276 

Unique Ingredient Identifier:

9P1872D4OL

Exenatide is a type of GLP1 agonists

GLP-1 agonists, short for glucagon-like peptide-1 agonists, are a subcategory of pharmaceutical APIs (active pharmaceutical ingredients) commonly used in the treatment of type 2 diabetes mellitus. These medications mimic the actions of GLP-1, a naturally occurring hormone in the body that helps regulate blood sugar levels.

GLP-1 agonists work by binding to GLP-1 receptors in the pancreas, promoting insulin secretion and inhibiting glucagon release. This mechanism of action leads to improved glucose control, reduced fasting and postprandial blood glucose levels, and decreased hemoglobin A1c levels.

One of the key advantages of GLP-1 agonists is their ability to promote weight loss in patients with type 2 diabetes. These medications slow down gastric emptying, increase satiety, and reduce food intake, resulting in modest but significant weight reduction.

Additionally, GLP-1 agonists have shown cardiovascular benefits, including a reduction in the risk of major adverse cardiovascular events, such as heart attack and stroke. They also exhibit a lower risk of hypoglycemia compared to some other antidiabetic medications.

Some commonly prescribed GLP-1 agonists include exenatide, liraglutide, dulaglutide, and semaglutide. These APIs are typically administered via subcutaneous injection, either once or twice daily, or in some cases, as weekly formulations.

In conclusion, GLP-1 agonists are a valuable class of pharmaceutical APIs used in the management of type 2 diabetes. Their mechanism of action, which includes glucose control, weight loss promotion, and cardiovascular benefits, makes them a favorable choice for patients seeking effective and safe antidiabetic therapy.

Exenatide (GLP1 agonists), classified under Anti-diabetics

Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.

• LGM Pharma from United States, product country of origin World
• Teva API from Israel, product country of origin Unknown
• Hainan Shuangcheng from China, product country of origin China
• Sun Pharma from India, product country of origin India
• Polypeptide Labs from Sweden, product country of origin India
• Mallinckrodt from United States, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.